Recital 9, Regulation (EU) 2015/1052

In forcesince 1 Jul 2015

Following an application from Jemo-pharm A/S submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effect of CranMax® and reduction of the risk of urinary tract infection by inhibiting the adhesion of certain bacteria in the urinary tract (Question No EFSA-Q-2013-00649) [EFSA Journal 2014;12(5):3657.]. The claim proposed by the applicant was worded as follows: ‘Prevent adhesion of E. coli to the uroepithelial cells in women which is a risk factor for developing urinary tract infections’.